ImmuCell Corp. (Nasdaq: ICCC), a Portland-based biotech company that makes health products for cattle, on Monday reported financial results that showed a 46% sales increase for the first quarter of 2022, compared with the same period in 2021.

Last quarter’s total hit a record high for the company, reaching $6 million, and continuing a trend that included a 45% sales increase for Q4 2021. Read more